Objective
Cancer can be considered a disease of gene control; since dysregulated patterns of gene expression are a feature of all tumours. Excitingly, targeting the underlying epigenetic mechanisms that promote oncogenic gene expression in cancer cells is providing significant opportunities for cancer drug development. Indeed, initial successes in this area may soon be leveraged for the benefit of cancer patients. Expanding European research capabilities in this area is essential, since approximately 1.5 million people die from cancer each year in Europe; and projections indicate that this number will increase in the coming decades. The work described in this application is at the cutting-edge of cancer drug target discovery, and drug development. My work identified the SWI/SNF complex component BRD9 as a novel drug target in several malignancies; and drug development efforts have led to first-in-class BRD9 degrader compounds. Testing the in vivo efficacy of these novel compounds as anti-cancer agents (WP1) will be essential if we are to translate these compounds to clinical investigations. Moreover, the work described in WP2/3 will be essential to fully exploit the potential of BRD9 as a drug target and identify additional opportunities for future drug development. My expertise in the areas of epigenetics and drug development make me the ideal candidate to pursue the outlined research program. Moreover, the support of this Action will give me the opportunity to develop further as an independent researcher; both in terms of technical expertise and transferable skills. These additional skills will allow me to achieve my long-term career goal of establishing my own independent research program, focusing on cancer epigenetics/drug development within a European context. Dissemination of the research findings associated with this Action will increase Europe's profile in cancer epigenetics research, and hopefully lead to increased public engagement in this important area of study.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences genetics epigenetics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
D02 CX56 Dublin
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.